modelC10BX07

Diagram of C10BX07

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:RosuvastatinAmlodipineAndLisinopril
ATC code:C10BX07
route:oral
compartments:1
dosage:10mg
volume of distribution:50L
clearance:20L/h
other parameters in model implementation

This is a fixed-dose combination drug that contains rosuvastatin (a statin for dyslipidemia), amlodipine (a calcium channel blocker for hypertension and angina), and lisinopril (an ACE inhibitor for hypertension and heart failure). The combination is used for treatment of cardiovascular risk factors such as hypercholesterolemia and hypertension. Such fixed-dose combinations may improve patient compliance. The combination is not widely available in all markets and approval status may vary by region.

Pharmacokinetics

No published pharmacokinetic studies or primary data reporting compartmental pharmacokinetic parameters for the triple fixed-dose combination of rosuvastatin, amlodipine, and lisinopril in healthy volunteers or patients. Typical PK parameters estimated from published values of individual drug monotherapies in adult healthy subjects. The values represent a general estimate.

References

    Parameters

    TypeNameDefaultDescription
    Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
    Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
    Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
    Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
    Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
    Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
    Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
    Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
    IntegeradminCount (from PK_1C)8number of dose administered (1)
    Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
    Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
    Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
    Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
    Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
    Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
    Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

    Connectors

    TypeNameDefaultDescription
    Types.ConcentrationOutputC_central (from PK_1C)
    Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

    Components

    TypeNameDefaultDescription
    Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
    Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
    Sources.PeriodicDoseperiodicDose (from PK_1C)
    Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

    Revisions

    • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)